Demonstration of enhanced endogenous fibrinolysis in thrombin activatable fibrinolysis inhibitor-deficient mice

Blood Coagulation and Fibrinolysis

Volumn 16, Issue 6, 2005, Pages 407-415

  Mao, Shi Shan ^a   Holahan, Marie A ^a   Bailey, Carolyn ^a   Wu, Guoxin ^a   Colussi, Dennis ^a   Carroll, Steven S ^a   Cook, Jacquelynn J ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Fibrinolysis; Mice; Thrombin activatable fibrinolysis inhibitor; Transgenic

Indexed keywords

BATROXOBIN; CARBOXYPEPTIDASE; FIBRINOGEN; THROMBIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBOMODULIN;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; BLOOD CLOTTING; CONTROLLED STUDY; DISEASE MODEL; FEMALE; FIBRINOLYSIS; IN VITRO STUDY; IN VIVO STUDY; LUNG EMBOLISM; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; WILD TYPE;

EID: 24044500304     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000181175.62437.2a     Document Type: Article

References (36)

1. Sueson E, Lutzen O, Thorsen S. Initial plasmin-degradation of fibrin as the basis of a positive feedback mechanism in fibrinolysis. Eur J Biochem 1984; 140:513-522.
2. Bouma BN, Marx PF, Mosier LO, Meijers JCM. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). Thromb Res 2001; 101:329-354.
3. Bajzar L. Thrombin-activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20:2511-2518.
4. Eaton DL, Malloy BE, Tsai SP, Henzel W, Drayna D. Isolation, molecular cloning, and partial characterization of a novel carboxypeptidase B from human plasma. J Biol Chem 1991; 266:21833-21838.
5. Bajzar L, Manuel R, Nesheim ME. Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor. J Biol Chem 1995; 270:14477-14484.
6. Bajzar L, Morse J, Nesheim ME. TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex. J Biol Chem 1996; 271:16603-16608.
7. Sakharov DV, Plow EF, Rijken DC. On the mechanism of the anti-fibrinolytic activity of plasma carboxypeptidase B. J Biol Chem 1997; 272:14477-14482.
8. Mao S-S, Cooper CM, Wood T, Shafer JA, Gardell SJ. Characterization of plasmin-mediated activation of plasma procarboxypeptidase B. J Biol Chem 1999; 274:35046-35052.
9. Wang W, Hendriks DF, Scharpe SS. Carboxypeptidase U, a plasma carboxypeptidase with high affinity for plasminogen. J Biol Chem 1994; 269:15937-15944.
10. Boffa MB, Wang W, Bajzar L, Nesheim ME. Plasma and recombinant thrombin-activatable fibrinolysis inhibitor (TAFI) and activated TAFI compared with respect to glycosylation, thrombin/thrombomodulin-dependent activation, thermal stability, and enzymatic properties. J Biol Chem 1998; 273:2127-2135.
11. Mao S-S, Colussi D, Bailey C, Bosserman M, Burlein C, Carroll SS. Electrochemiluminescence assay for basic carboxypeptidases: inhibition of basic carboxypeptidases and activation of thrombin-activatable fibrinolysis inhibitor. Analyt Biochem 2003; 319:159-170.
12. Nagashima M, Yin Z-F, Zhao L, White K, Zhu Y, Lasky N, et al. Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life. J Clin Invest 2002; 109:101-110.
13. Carmeliet P, Stassen JM, Schoonjans L, Ream B, van den Oord JJ, de Mol M, et al. Plasminogen activator inhibitor-1 gene-deficient mice. J Clin Invest 1993; 92:2756-2760.
14. 2- Antiplasmin gene deficiency in mice is associated with enhanced fibrinolytic potential without overt bleeding. Blood 1999; 93:2274-2281.
15. Lenfors S, Gustafsson D. New model for in vivo studies of pharmacological interventions with endogenous fibrinolysis: effects of thrombin inhibitors. Semin Thromb Hemost 1996; 22:335-342.
16. Nakatani Y, Fujioka M, Higashino K. Enzymic determination of L-lysine in biological materials. Anal Biochem 1972; 49:225-231.
17. Holleman WH, Weiss U. The thrombin-like enzyme from Bothrops atrox snake venom. Properties of the enzyme purified by affinity chromatography on p-aminobenzamide-substituted agarose. J Biol Chem 1976; 251:1663-1669.
18. Redlitz A, Tan AK, Eaton DL, Plow EF. Plasma carboxypeptidases as regulators of the plasminogen system. J Clin Invest 1995; 95:2534-2538.
19. Redlitz A, Nicolini FA, Malycky JL, Topol EJ, Plow EF. Inducible carboxypeptidase activity: a role in clot lysis in vivo. Circulation 1996; 93:1328-1330.
20. Wang W, Boffa MB, Bajzar L, Walker JB, Nesheim ME. A study of the mechanism of inhibition of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J Biol Chem 1998; 273:27176-27181.
21. Hendricks D, Scharpé S, van Sannde M, Lommaert MP. Characterisation of a carboxypeptidase in human serum distinct from carboxypeptidase N. J Clin Chem Clin Biochem 1989; 27:277-285.
22. Mosnier LO, von dem Borne PAK, Meijers JCM, Bouma BN. Plasma TAFI levels influence the clot lysis time in healthy individuals in the presence of an intact intrinsic pathway of coagulation. Thromb Haemost 1998; 80:829-835.
23. Meade TW, Ruddock V, Stirling Y, Chakrabarti R, Miller GJ. Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study. Lancet 1993; 342:1076-1079.
24. Schatteman KA, Goossens FJ, Scharpe SS, Hendriks DF. Activation of plasma procarboxypeptidase U in different mamalian species points to a conserved pathway of inhibition of fibrinolysis. Thromb Haemost 1999; 82:1718-1721.
25. Romson JL, Haack DW, Lucchesi BR. Electrical induction of coronary artery thrombosis in the ambulatory canine: a model for in vivo evaluation of antithrombotic agents. Thromb Res 1980; 17:841-853.
26. Mattsson C, Bjorkman JA, Abrahamsson T, Nerme V, Schatteman K, Leurs J, et al. Local proCPU (TAFI) activation during thrombolytic treatment in a dog model of coronary artery thrombosis can be inhibited with a direct, small molecule thrombin inhibitor (melegatran). Thromb Haemost 2002; 87:557-562.
27. Minnema MC, Friederich PW, Levi M, von dem Borne PAKr, Mosnier LO, Meijers JCM, et al. Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. J Clin Invest 1998; 101:10-14.
28. Klement P, Liao P, Bajzar L. A novel approach to arterial thrombolysis. Blood 1999; 94:2735-2743.
29. Nagashima M, Werner M, Wang M, Zhao L, Light DR, Pagila R, et al. An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model. Thromb Res 2000; 98:333-342.
30. Refino CJ, DeGuzman L, Schmitt D, Smyth R, Jeet S, Lipari MT, et al. Consequences of inhibition of plasma carboxypeptidase B on in vivo thrombolysis, thrombosis and hemostasis. Fibrinol Proteol 2000; 14:305-314.
31. Hashimoto M, Yamashita T, Kazuhiro O, Watanabe S, Giddings JC, Yamamoto J. Enhancement of endogenous plasminogen activator-induced thrombolysis by argatroban and APC and its control by TAFI, measured in an arterial thrombolysis model in vivo using rat mesenteric arterioles. Thromb Haemost 2002; 87:100-103.
32. Nerme V, Akerblom B, Abrahansson T. The combined inhibition of carboxypeptidase U and thrombin increases synergistically the rate of fibrinolysis in a rat DIC model [Abstract]. Fibrinol Proteol 2000; 14(suppl 1):69.
33. Wu C, Dong N, da Cunha V, Martin-McNulty B, Tran K, Nagashima M, et al. Activated thrombin-activatable fibrinolysis inhibitor attenuates spontaneous fibrinolysis of batroxobin-induced fibrin deposition in rat lungs. Thromb Haemost 2003; 90:414-421.
34. Gresele P, Momi S, Berrettini M, Nenci GG, Schwarz HP, Semeraro N, Colucci M. Activated human protein C prevents thrombin-induced thromboembolism in mice. J Clin Invest 1998; 101:667-676.
35. Marx PF, Wagenaar GT, Reijerkerk A, Tiekstra MJ, van Rossum AGSH, Gebbink MFBG, Meijers JCM. Characterization of mouse thrombin-activatable fibrinolysis inhibitor. Thromb Haemost 2000; 83:297-303.
36. Swaisgood CM, Schmitt D, Eaton D, Plow EF. In vivo regulation of plasminogen function by plasma carboxypeptidase B. J Clin Invest 2002; 110:1275-1282.